ClinicaliQ Trial Snapshot
- Avr Thrombosis OutcoMe Study — Recruiting • Cardiology / Cardiovascular • NCT04234841.
- What is being tested: Novel blood biomarkers that assess thrombosis and thrombolysis activity to identify patients at high risk of thrombotic complications following surgical aortic valve replacement (SAVR) or transcatheter aortic valve implantation (TAVI).
- Patient eligibility overview: The study recruits patients undergoing either SAVR or TAVI procedures for aortic valve disease, enabling comparison of thrombotic risk profiles between these two treatment approaches.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study aims to utilise novel biomarkers assessing thrombosis and thrombolysis (through a blood test), to identify patients undergoing either surgical aortic valve replacement (SAVR) or transcatheter aortic valve implantation (TAVI) who are at risk of thrombosis, and relate this to clinical thrombotic and thromboembolic adverse events and subclinical valve thrombosis, and identify the timeframe of greatest risk for valve thrombosis.
Eligibility Snapshot
- : 1. Male and female patients aged 18 years or over. 2. Patients diagnosed with aortic valve disease, undergoing surgical or transcatheter AVR and free of
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.